NCT01527552View on ClinicalTrials.gov

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 5, 2002

Primary Completion Date

December 18, 2002

Study Completion Date

December 18, 2002

Conditions
DiabetesHealthy
Interventions
DRUG

biphasic insulin aspart 50

A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days

Trial Locations (1)

9324

Novo Nordisk Investigational Site, Bloemfontein

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01527552 - Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter